|
?:abstract
|
-
[ ]any discussion of clozapine and agranulocytosis risk must be couched in a historical perspective Competing interests: G Remington has received clinical, research and advisory board support from HLS Therapeutics, consultant fees from Mitsubishi-Tanabe Pharma Corporation, and research support from the University of Toronto, Canadian Institutes of Health Research (CIHR) and Research Hospital Fund-Canada Foundation for Innovation (RHF-CFI) [ ]we have encouraged prescribers, patients and families/carers to reflect on the risks and benefits for individual cases Affiliations: From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind);the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles);the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer);the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane);the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane);the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll);the Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll);the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hasan);the Institute of Psychiatry, Psychology & Neuroscience, King\'s College London, London, UK (Howes);the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes, MacCabe);the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes);the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly);the Bronx Westchester Medical Group, New York, USA (Laitman);the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee);the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee);the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark (Nielsen);the Mental Health Service NoordHolland-Noord, Alkmaar, The Netherlands (Schulte);the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor);the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux);the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler);the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA (Freudenreich);and the Harvard Medical School, Boston, Massachusetts, USA (Freudenreich)
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}